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Identifying and developing emerging biotechnologies is important in improving health in 
the poorest nations because current health products and practices are generally not 
suited for their developing economies, their inadequate transport and power 
infrastructures, their largely rural populace, and their rugged and often tropical 
environments.  Advances in biotechnology will more likely be valued and adopted as 
innovations in developing countries if they are suited to these challenging conditions.  
These innovations in health will favor a shift away from a centralized, curative-based 
framework towards a decentralized, prevention-based paradigm.  In this article, 
advances in microfluidics and in vaccine delivery and storage are highlighted within the 
context of disease diagnosis and prevention in the developing world. 
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Introduction: 
 What is the link between scientific discovery, biotechnology, and innovation? Why is 
biotechnology particularly important for improving health in the world’s poorest nations? 
One can think of scientific discovery and innovation as being on two opposite sides of a 
continuum.   Scientific discovery deals with acquiring new knowledge by correcting and integrating previous 
knowledge through the formulation of testable hypotheses, conducting experiments, collecting data, and 
interpreting results in order to form conclusions; it is largely carried out in universities and is often 
characterized by academic freedom and intellectualism.  On the other end of that continuum lies innovation, 
which introduces a new product or process that is both valuable to adopters and disruptive to the status quo.   
Unlike scientific discovery, innovation is driven by economic and social pressures, which creates wealth or 
social welfare to a group of people, an organization, or a society by improving quality, efficiency, and 
productivity.   
In the middle of the continuum lies translational research, where discoveries with potential value are 
identified and pursued; this is largely conducted by the private sector.  In the context of health products and 
practices, this middle ground is the domain of biotechnology.  Innovations in products such as vaccines, 
medical devices, and equipment start from scientific discoveries in genomics-related sciences and in applied 
sciences or engineering. Advances in biotechnology become innovations if they are considered valuable in 
demonstrating clinical efficacy, ease of administration and use, reducing costs, and so on; these are adopted 
by health workers, health ministries, companies, and organizations.  
Unlike scientific discovery, which is a long-term investment associated with high-risks, advances in 
biotechnology may directly lead to innovation and therefore contribute value to health sooner rather than 
later. More importantly, however, developing countries cannot sustain the adoption of medical products 
that are conventional in developed countries.  These products and practices are incompatible with their 
weak economies, their underdeveloped transport and power infrastructures, their largely poor and rural 
populations, and their rugged and often tropical environments.   
Despite these challenges, developing countries are perhaps best positioned to adopt innovations in 
biotechnology.  Not only do their circumstances pose significant challenges that demand creative and 
valuable solutions, but the significant gains over health products and practices currently inadequate or 
nonexistent in developing countries may also accentuate the value of an innovation.  Specifically, this value 
can range from reducing early mortality and burden of disease with more effective recombinant vaccines, to 
preventing degradation of vaccines by creating and optimizing techniques for stable formulations that 
withstand large fluctuations in heat and humidity, to increasing portability and capability of diagnostic 
devices with miniaturized lab-on-a-chip technology.  
In short, the impetus for innovation in health is vast. In fields other than those associated with 
healthcare, there has already been widespread adoption of relevant innovations.  For example, the adoption 
of cell phones and wireless internet in Sub-Saharan Africa has replaced the historical precedent of 
developing landlines, thereby allowing for quick communication to places in rugged and remote regions, 
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without the need to develop significant infrastructure2.  However, the mere adoption of technology may not 
be enough to develop appropriate health products; perfecting promising biotechnologies and even 
developing new ones may be necessary.  In doing so, developing countries may be able to bypass medical 
technologies conventional to centralized health systems, such as hospitals for healthcare and labs for 
diagnostic results, and instead be able to develop innovative technology better-suited for decentralized 
health networks, such as point-of-care diagnosis and at-home healthcare, which emphasize cost-effective 
public health strategies such as disease prevention and epidemiological surveillance3.   
In identifying and developing promising biotechnologies, it is important to first understand the 
limitations of conventional health products in meeting the unique challenges in the developing world.  
These limitations can be divided into several major categories:  (1) power (e.g. lack of ground electricity, lack 
of refrigeration), (2) ease of use/administration (e.g. lack of skilled workers), (3) efficacy (e.g. sensitivity and 
specificity for diagnostics, development of immunity for vaccines), (4) portability (e.g. potential for use at 
rural villages or at point-of-care), (5) cost (e.g. costs associated with the product itself versus those for 
peripherals), and (6) safety.  
This paper focuses on identifying two active areas of biotechnology research relevant to health in 
developing countries: vaccines for building immunity against infectious diseases and microfluidics for point-
of-care diagnostics.  Each section highlights the limitations of current products in the settings of developing 
countries, and discusses the advantages and possible disadvantages emerging biotechnologies have in this 
setting. 
 
Vaccines: Novel storage and delivery strategies 
Vaccines for childhood illnesseswidely considered as essential in any strategy for disease 
prevention in developing and developed countries alikehave benefited greatly from recombinant DNA 
technologies.  Not only are recombinant vaccines4 already proving to be cheaper in testing and scale-up of 
production, as well as safer (particularly in immunocompromised individuals) than inactivated or attenuated 
vaccines5, they may also address problems with vaccine storage and delivery.  Normally, vaccines require 
refrigeration, needles, and multiple administrations to fortify or refresh immunity. In much of the 
developing world, however, refrigeration is unavailable, and when available, refrigeration can constitute up 
to 80 percent of the total cost of vaccine delivery5. Needles are often misused by inexperienced personnel in 
                                                
2 UNDP, Human Development Report 2001:  Making New Technologies Work for Human Development. 2001, United Nations 
Development Programme: New York. 
and  
Chin, C.D., V. Linder, and S.K. Sia, Lab-on-a-chip devices for global health: past studies and future opportunities. Lab 
Chip, 2007. 7(1): p. 41-57. 
3 Alwan, A. and B. Modell, Recommendations for introducing genetics services in developing countries. Nat Rev 
Genet, 2003. 4(1): p. 61-8. 
4 Recombinant vaccines are created by genetically modifying microorganisms such as bacteria and yeast and 
stimulating them to produce large quantities of immunogenic proteins. 
5 Daar, A.S., et al., Top ten biotechnologies for improving health in developing countries. Nat Genet, 2002. 32(2): p. 
229-32. 
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unsanitary conditions, leading to transmission of blood-borne pathogens such as HIV, HBV, and HCV6.  
Patient noncompliance is commonplace with poor rates of return visits, thereby making multiple vaccine 
administrations difficult. 
These issues can be partially addressed by developing novel storage techniques or by optimizing 
established processes with new formulations in order to increase vaccine viability, and by researching 
different methods of vaccine administration to reduce the need for intravenous immunizations.  For 
example, the Bacillus Calmette-Guérin vaccine7 (BCG) is currently prepared commercially by freeze-
drying8, which is known to significantly reduce BCG viability after freezing.  Researchers at Harvard 
University hypothesize that the presence of nonvolatile salts and cryoprotectants during the normal drying 
of droplets raised osmotic pressures high enough to damage bacterial membranes, which yield low vaccine 
viability and stability at room temperature9.  They discovered that spray drying with a special protein 
matrix without salts and cryprotectants yielded improved viability and stability9.  This is promising, given 
the potential of spray-dried vaccines to be inhaled rather than administered intravenously, and scaled-up in 
sterile conditions with lower operating costs as compared to freeze-drying methods10 ,11.  Already, Medicine 
in Need12  plans to develop stable cell dry powder vaccine formulations for efficient and noninvasive inhaled 
delivery.  Furthermore, recent studies have demonstrated the effectiveness of porous particles and 
nanoparticles in efficiently delivering therapeutic aerosols, with the potential for larger dose delivery13 ,14 ,15. 
Besides pulmonary vaccine delivery, other needle-free methods of immunization in the developing 
world such as liquid-jet injection, epidermal powder immunization, topical application (through cutaneous 
routes), and oral and nasal immunizations (through mucosal routes) have been proposed as alternatives to 
intravenous immunizations6.  Liquid-jet injections use the kinetic energy from a high velocity vaccine jet 
(typically up to 100 m/s, with a microneedle tip) to penetrate the skin and deliver the vaccine intradermally, 
subcutaneously, or intramuscularly.  Targeting the skin promotes its contact with Langerhans cells, which 
initiate specific immune responses by processing and presenting antigen fragments to naïve T-cells in the 
lymph nodes.  Vaccines delivered by liquid-jet usually spread over a larger tissue area than vaccines 
                                                
6 Mitragotri, S., Immunization without needles. Nat Rev Immunol, 2005. 5(12): p. 905-16. 
7 BCG vaccine is against tuberculosis which is prepared from a strain of the attenuated live bovine tuberculosis bacillus. 
8 Freeze-drying (also known as lyophilization) is a common dehydration process used to preserve a sensitive material 
and make transport convenient.  Freeze-drying involves a two-step process:  1) freezing below the lowest temperature at 
which solid and liquid phases can coexist (eutectic point), and 2) sublimination of ice crystals to water vapor. 
9 Wong, Y.L., et al., Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci U S A, 2007. 104(8): p. 2591-5. 
10 Millqvist-Fureby, A., M. Malmsten, and B. Bergenstahl, An aqueous polymer two-phase system as carrier in the spray-drying of 
biological material. Journal of Colloid and Interface Science, 2000. 225(1): p. 54-61. 
11 Vanbever, R., et al., Formulation and physical characterization of large porous particles for inhalation. Pharm Res, 1999. 16(11): 
p. 1735-42. 
12 Medicine in Need is a non-governmental organization founded by David Edwards, the principal investigator of the 
aforementioned study. 
13 Edwards, D.A., et al., Large porous particles for pulmonary drug delivery. Science, 1997. 276(5320): p. 1868-71.  
14 Pulliam, B., J.C. Sung, and D.A. Edwards, Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug 
Deliv, 2007. 4(6): p. 651-663. 
15 Tsapis, N., et al., Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A, 2002. 
99(19): p. 12001-5. 
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administered with needles, and may allow more contact with antigen-presenting cells before being 
degraded.  While many vaccines (e.g. influenza and hepatitis B) have been successfully delivered using 
liquid-jets, cross-contamination and cost are major limitations.  The development of disposable-cartridge jet 
injectors and single-use, pre-filled disposable devices have sought to alleviate concerns about contamination.   
Epidermal powder immunizations facilitate storage of vaccine powders and there is strong clinical 
evidence for its applicability in DNA vaccines; however, non-DNA vaccines have enjoyed little commercial 
success.  Topical vaccine application, like liquid-jet and epidermal powder immunizations, naturally target 
Langerhans cells and are cheaper and easier to use. However, simple topical delivery yields an inadequate 
immune response due to the low permeability of the stratum corenum, the outer layer of the skin.  Current 
research includes using topically applied adjuvants16, colloidal carriers17, and physical methods such as 
microneedles, ultrasound, and electroporation with topical application6,18. 
Oral vaccine delivery has been used for live attenuated pathogens such as polio and typhoid, and is 
attractive because of its simplicity and ease of administration.  However, vaccines are degraded and 
deactivated in the acidic gastrointestinal environment and high doses are required for adequate immune 
responses; improving response variability is an active area of research.  Nasal delivery allows easier access to 
mucosal membranes than does oral delivery, but the short contact time and enzymatic activity, while less 
relative to that in gastrointestinal tract, poses considerable challenges which have yet to be overcome6. 
A subset of oral vaccine delivery is temperature-stable formulations of vaccines expressed in 
transgenic organisms such as plants or crops19 ,20.  Edible vaccines are attractive because they are easy to 
administer; they are also theoretically cheap to produce because no protein purification steps are needed.  
Studies on edible plant vaccines have shown to stimulate immunogenic responses against the hepatitis B 
virus and Norwalk virus, which causes diarrhea.  They also have protective capacity against pathogens 
causing bacterial diarrhea, such as cholera and enterotoxigenic Escherichia coli21,22 , and tetanus toxin 
produced by bacterium Clostridium tetani23.  The latter is a common childhood vaccination target along with 
diptheria and pertussis.  Ongoing research aims to (1) understand variations in vaccine stability and 
immunogenicity in mucosal delivery, (2) express higher levels of antigen, (3) guard against degradation of 
protein components in the stomach and gut before they can elicit an immune response22, and (4) 
understand the risks of genetic contamination of foodstuffs and the threats to biodiversity. 
                                                
16 An adjuvant is an agent that is mixed with an antigen and increases the immune response to that antigen following 
immunization6 
17 A colloidal carrier is a stable system of small particles of lipds, polymers or any other material that encapsulate a 
vaccine6 
18 Guy, B., The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol, 2007. 5(7): p. 505 
19 Acharya, T., A.S. Daar, and P.A. Singer, Biotechnology and the UN's Millennium Development Goals. Nat Biotechnol, 2003. 
21(12): p. 1434-6. 
20 Acharya, T., et al., Strengthening the role of genomics in global health. PLoS Med, 2004. 1(3): p. e40. 
21 Mason, H.S., et al., Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends 
Mol Med, 2002. 8(7): p. 324-9. 
22 Daniell, H., S.J. Streatfield, and K. Wycoff, Medical molecular farming: production of antibodies, 
biopharmaceuticals and edible vaccines in plants. Trends Plant Sci, 2001. 6(5): p. 219-26. 
23 Tregoning, J.S., et al., Protection against tetanus toxin using a plant-based vaccine. Eur J Immunol, 2005. 35(4): p. 1320-6. 
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Diagnostics: Microfluidic devices 
Another promising biotechnology is microfluidics for development of portable and cheap health 
diagnostics2,24.  Microfluidics deals with the behavior and precise manipulation of small volumes of liquids 
and gases moving through microchannels embedded in a chip.  Also known as “lab-on-a-chip”, microfluidic 
devices have the potential to automate complex laboratory tasks such as sample preparation, pre-
concentration, and analyte detection (i.e. detection of desired biomarkers, such as antibodies against 
hepatitis B, conserved nucleic acid sequences in malaria parasites, T-cells for monitoring HIV/AIDS, etc.) 
on a chip.  Usually, these laboratory tasks require bulky, mechanically complex, expensive, power-draining 
instruments, such as centrifuges (e.g. for sample preconcentration), vortexes and spinners (e.g. for mixing 
liquids), liquid-handling robots (e.g. for quantifying protein in benchtop immunoassays), thermocyclers (e.g. 
for amplifying nucleic acids), flow cytometers (e.g. for counting and sorting cells), and high-powered 
microscopes (e.g. for visualizing cells).  A true “lab-on-a-chip” would allow health workers in developing 
countries to run common lab tests with greater accuracy and throughput without significant prior training 
(Figure 1).   
Furthermore, miniaturizing onto a battery-powered or even solar-powered handheld device would 
allow health workers to diagnose at point-of-care, reducing time spent waiting for results and the number of 
patient visits to the clinic (Figure 1A).  The time saved is on the order of days in situations where samples 
need to be sent to national and/or regional testing centers25 for processing.  Clinics with poor patient 
compliance in follow-up visits may particularly benefit because diagnosis and treatment prescriptions can be 
done on a single visit.  Additionally, microfluidic diagnostic devices could be employed in a decentralized 
health care system where health workers travel to the village or rural home to deliver care. 
Even in situations where the testing center has the capacity to run the desired assay, microfluidic 
diagnostics still save time by integrating multiple tasks and by processing microliter to nanoliter volumes.  
At these small volumes, reactions are rarely diffusion-limited, allowing for faster kinetics particularly when 
catalysts are involved, and thermal mass is minimized, allowing quicker responses to heat changes e.g. in 
thermocycling for PCR26.  The ability to process small volumes also allows for less invasive patient 
sampling procedures such as fingerpricks as compared to more invasive techniques such as intravenous 
blood draws (Figure 1A). 
Most studies to date have focused on particular microfluidic procedures such as fluid actuation, 
mixing, sample preparation, analyte detection, because each poses tremendous scientific and technical 
                                                
24 Yager, P., et al., Microfluidic diagnostic technologies for global public health. Nature, 2006. 442(7101): p. 412-8. 
25 The quality, conditions, and types of tests performed at health centers usually correlates with degree of urban 
development2. 
26 PCR, or polymerase chain reaction, is a technique used for detection of nucleic acids (PCR for DNA, RT-PCR for 
RNA), typically for determining infection and pathogen strain or subtype identification.  A section of target DNA is 
marked off with flanking DNA primers and amplified exponentially with repeated heating and cooling patterns 
(thermocycles). 
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challenges and depends on the physical, chemical, and biological makeup of the analyte2.  With extensive 
work on new strategies and characterization, researchers are looking to integrate multiple procedures in 
order to be able to detect multiple analytes on a single chip (as illustrated in Figure 1B).  Analytes are divided 
roughly into four classes:  (1) cells, (2) metabolites, (3) nucleic acids, and (4) metabolites27.  Each class of 
biomarker is described in terms of its importance in diagnosing infections and health conditions, and 
significant research advances relevant to the advancement of global health are identified. 
 
 
Figure 1:  Microfluidics:  an emerging technology in portable, low-cost diagnostics.  A:  Proposed intervention of device in 
workflow.  B:  Ability of microfluidics to carry out multiple tests rapidly; cells, metabolites, nucleic acids, and proteins can all 
be analyzed for a complete diagnosis. 
 
Cells: 
Cell counts are important measures in addressing anemia and hematology via red blood cell and 
complete blood counts, as well as in monitoring HIV-infected patients for structuring antiretroviral 
treatment regimens via CD4+ T-cells. One study suggests that differential shear flows on antibody-
functionalized surfaces can selectively capture CD4+ T-cells without labeling in a simple microfluidic 
                                                
27 For a more detailed discussion on microfluidic diagnostic technologies for global health, see references 8 and 21. 
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format28.  Cell analysis via microscopic examination is important for parasitology (e.g. blood smears for 
malaria).  Additionally, microbiological culture is important for determining drug-resistant strains of 
bacteria (e.g. tuberculosis, Staph A), because culture is still considered the “gold standard” relative to newer 
molecular-based techniques detecting nucleic acids. 
Small Molecules: 
Detection of small molecules is important for monitoring blood chemistries.  Common targets 
include bicarbonate for regulating pH, sodium and potassium for maintaining specific electrolyte levels in 
nerve and muscle function, oxygen and carbon dioxide for determining respiratory and/or metabolic 
problems, and glucose for metabolic disorders such as diabetes.  Vitamins and minerals are also relevant 
targets for detection, as they allow for the diagnosis and monitoring of nutritional deficiencies.  Popular 
techniques include electrochemical detection using thin-film patterned electrodes.  iSTAT, a current 
commercial product produced by Abbot Diagnostics, employs this specific technique. 
Nucleic Acids: 
Conserved DNA or viral RNA sequences are often targets for detecting specific infectious diseases 
and for determining the stage of a disease (e.g. HIV RNA viral load).   Genotyping is also common for 
distinguishing between pathogen strains (e.g. Hepatitis C).  The most popular techniques are PCR and RT-
PCR, due to their intrinsic specificity and signal amplification.  Certain technical challenges include the 
need for sample pre-treatment of lysed cells and low-cost methods for portable signal amplification and 
detection.  One study demonstrates that oligonucleotide-conjugated nanoparticle probes coupled with silver 
reduction amplification can yield a low-cost and sensitive system29. 
Proteins: 
Antibody and antigen markers can indicate infections predominant in developing countries (such 
as anti-HIV antibodies, gp41 and gp120 antigens for HIV).  One study uses a gold-silver sandwich 
immunoassay for detecting αHIV-1 antibodies in a microfluidic setup.  The opacity of the solution due to 
silver reduction correlated with the amount of antibody in patient serum and was read by a simple, low-cost 
absorbance reader30. 
Cost-reduction is perhaps the most attractive quality of microfluidic diagnostic devices.  Typically, 
one-time purchases of fixed instruments range from tens to hundreds of thousands of US dollars.  For 
example, the cost of reagents is $5 for immunoassays and $50-300 for nucleic acid tests in a typical in-house 
hospital laboratory in the developed world2.  In contrast, microfluidic devices in the developing world 
would need fixed instrument31 costs at tens of dollars, and per-assay32 costs on the order of pennies, which 
                                                
28 Cheng, X., et al., A microfluidic device for practical label-free CD4(+) T cell counting of HIV-infected subjects. Lab 
Chip, 2007. 7(2): p. 170-8. 
29 Taton, T.A., C.A. Mirkin, and R.L. Letsinger, Scanometric DNA array detection with nanoparticle probes. Science, 2000. 
289(5485): p. 1757-1760. 
30 Sia, S.K., et al., An integrated approach to a portable and low-cost immunoassay for resource-poor settings. Angew 
Chem Int Ed Engl, 2004. 43(4): p. 498-502. 
31 Fixed instrument consists of hardware components for analyte detection, fluid actuation, power, and electronics for 
signal enhancement, user interfacing, and data tranmission. 
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would include both chips and reagents.  By scaling down reagent volumes hundred- to thousand-fold and 
by using cheaper materials, such as injection-moulded plastics instead of glass, quartz, and silicon, and 
electrical components2 (Figure 1A), the costs associated to fixed instrument and assay are reasonable for 
device deployment in limited-resource settings. 
 Implementing an appropriate intervention of microfluidic diagnostics, or of any new technology, 
in the health networks of developing countries is far from trivial.  Figure 1A illustrates some of the 
considerations for a lab-on-a-chip both in and out of the clinic.  For instance, it is necessary to minimize the 
number of moving parts needed on the chip and in the reader in order to design an easily operated device. 
Also, a minimal user interface consisting of a few buttons for powering and operation, and signal lights for 
showing status of test, on the reader itself may make the device easier for an untrained health worker to 
operate. 
Considerations downstream of the microfluidic assay include recording, storing, and 
communicating results (Figure 1A).  Typically, most centralized testing sites and practically all rural testing 
sites rely solely on written records, but digital records could improve quality of care (by assuring evidence-
based medicine) and expedite communication, particularly in disease surveillance, where communication of 
results between clinics is vital33.  Results that are typed, synced via USB storage key, or uploaded via 
wireless transmission to a computer can then be collected and stored locally on a clinic-level network 
database.  Periodically, local networks of electronic records can communicate periodically with other clinics 
through syncing or internet upload.   
D-Tree International, a non-governmental organization dedicated to improving medical records 
management in developing countries, plans to train and equip frontline providers with personal digital 
assistants, smart cards, and back up systems for sending data in real-time.  This non-profit organization also 
develops evidence-based, standardized diagnostic and treatment protocols customized for local cultural 
conditions such as language, epidemiological patterns, and drug lists,  also taking into account resources by 
calculating drug dosage based on patient statistics. 
Technology is one part of the solution and must be designed appropriately to its settings (Figure 2).  
For example, backup batteries and dust covers (Figure 2A) are common in many regional and rural testing 
centers.  This highlights performance and design considerations in alternative power, using backup batteries 
which may be rechargeable or even solar-powered, and dusty environments.  Bench-top units are fine in 
centralized testing centers but cannot be transported to rural sites.  Flow cytometers (Figure 2B) are bulky 
and expensive, complicated to use, and are often in English instead of native languages.  It is also clear that 
many diagnostic tests require significant training and are inadequate due to their lack of specificity. For 
instance, malaria blood smears are widely performed, and yet are difficult to read due to the subtle 
differences in phenotype between erythrocytes infected with different Plasmodium species.  One alternative to 
                                                                                                                                            
32 Assay components include chips (which can be reused depending on the material and application) and reagents. 
33 Initiatives such as One Laptop Per Child (headed by John Negroponte, head of MIT’s Media Lab) may also help 
close the digital divide. 
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microscopes and blood smears may be detecting differences in cell deformability, or electrical properties by 
using microfluidic setups34 ,35. 
 
Figure 2: Design constraints depend on circumstances in the developing world (pictures of labs).  A:  Lab at Kicukiro (outside 
Kigali, Rwanda) relies on backup batteries and dust covers.  B:  Flow cytometer at Gisenyi (regional test center in Rwanda) is 
                                                
34 Shelby, J.P., et al., A microfluidic model for single-cell capillary obstruction by Plasmodium falciparum-infected 
erythrocytes. Proc Natl Acad Sci U S A, 2003. 100(25): p. 14618-22. 
35 Gascoyne, P., J. Satayavivad, and M. Ruchirawat, Microfluidic approaches to malaria detection. Acta Tropica, 2004. 89(3): 
p. 357-369. 
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bulky, expensive, difficult to use, and uses English instead of the local French or Kinyarwanda.  C:  Malaria blood smears are 




There is a need for scientific innovation in global health, and the identification of key emerging 
technologies in diagnosis and prevention are the first steps.   Technologies need to be relevant to local 
conditions, and developing countries have a unique set of challenges that advances in biotechnology need to 
address before they become valuable as innovations.  The need for biotechnologies that can be compatible 
to a decentralized, prevention-based health paradigm is evident because a conventional health system is 
unsustainable and incompatible with a developing nation’s budget, environment, and demographics. 
Beyond identifying key biotechnologies, their development goes hand in hand with other efforts for 
improving health infrastructures.  Training programs are critical for improving skills of health workers, 
particularly in rural areas, and new technologies intended to work in these circumstances need to be 
introduced and involved at an early stage.  Faster and reliable communication and data storage systems will 
improve epidemiological surveillance and allow health workers to better customize diagnoses and 
treatments based on statistics pertinent to specific patients, as well as the local population as a whole.  
Health education and awareness programs are important cost-effective interventions for stressing disease 
prevention and healthy lifestyles, and new technologies need to be understood by the populations they 
serve, in terms of access, changes in healthcare, and the potential positive and negative health side effects.  
A multidisciplinary approach with biotechnology is important for sustained and comprehensive 
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